This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
The model inputs assessed in the review were: H. pylori prevalence; the eradication success rate with triple therapy; the healing rate with lansoprazole and famotidine; the annual relapse rate after eradication success and no treatment, or after eradication failure and no treatment; and the 6-month relapse rate after H2RA maintenance therapy.
Study designs and other criteria for inclusion in the review
The study designs of the primary studies were not reported. The authors conducted two reviews of the literature. The first review aimed to identify data concerning relapse rates after eradication success or failure. The second literature review searched data on healing or relapse rates with famotidine. The inclusion criteria for the first review were:
H. pylori-positive gastric and duodenal ulcers; single, double or triple H. pylori eradication therapy; the use of an H. pylori testing method (culture, histology, rapid urease test or urea breath test) before and after eradication therapy; the presence or absence of H. pylori was checked at 4 weeks after H. pylori eradication therapy; 12-month follow-up with no treatment; and endoscopic examination for ulcer relapse.
The inclusion criteria for the second review were: gastric and duodenal ulcers; single-or double-blind trial; healing (famotidine, 40 mg/day) and maintenance (famotidine, 20 mg/day) therapy; randomised trial; endoscopic examination for ulcer relapse; and a sample size larger than 20 for each group. 
Sources searched to identify primary studies

Criteria used to ensure the validity of primary studies
Not stated.
Methods used to judge relevance and validity, and for extracting data
In extracting data from the primary studies, a conservative stance towards eradication policy was adopted in order to 
Number of primary studies included
The reviews included 33 primary studies.
Methods of combining primary studies
The data on relapse rates were pooled separately, with each rate weighted by the inverse of its variance. A constant hazard was assumed when the annual or 6-month pooled relapse rates were converted into rates at 8 or 6 weeks.
Investigation of differences between primary studies
Not carried out.
Results of the review
In the case of gastric ulcer:
the H. pylori prevalence was 94.3%;
the eradication success rate with triple therapy was 87.5% (95% confidence interval, CI: 79.2 -93.4);
the healing rate was 91.9% with lansoprazole and 80.5% with famotidine;
the annual relapse rate was 5.5% after eradication success and no treatment, and 52.3% after eradication failure and no treatment;
the 6-month relapse rate after H2RA maintenance therapy was 24%.
In the case of duodenal ulcer:
the H. pylori prevalence was 98.7%;
the eradication success rate with triple therapy was 91.1% (95% CI: 83.2 -96.1); the healing rate was 96.6% with lansoprazole and 82.5% with famotidine;
the annual relapse rate was 2.9% after eradication success and no treatment, and 78.4% after eradication failure and no treatment;
the 6-month relapse rate after H2RA maintenance therapy was 21%.
Methods used to derive estimates of effectiveness
The authors made some assumptions on the basis of expert opinion and Japanese practice methods.
Estimates of effectiveness and key assumptions
It was assumed that:
95% of symptomatic patients had ulcer relapses (this was extracted from an earlier study); 5% of the patients who received eradication therapy dropped out due to adverse events and switched to conventional therapy; and decision models. In the gastric ulcer model, the cost per DFD was Y117 with eradication therapy and Y298 with conventional therapy. The corresponding costs in the duodenal ulcer model were Y90 (eradication therapy) and Y234 (conventional therapy), respectively. However, the eradication therapy was dominant because it was associated with lower costs and higher effectiveness than the conventional therapy in both patients groups. These results were robust to the variations investigated in the sensitivity analysis.
Authors' conclusions
From the perspective of the health service payer, eradication therapy for Helicobacter pylori (H. pylori) was more costeffective than the conventional therapy used for patients with either gastric or duodenal ulcer in Japan. The authors estimated that the treatment of all gastric and duodenal ulcers with eradication therapy, rather than conventional therapy, would save about 320 yen in Japan over a 5-year period.
CRD COMMENTARY -Selection of comparators
The rationale for the choice of the comparators was clear. H2RA therapy was selected because it represented the conventional approach used in Japan before combination eradication therapy was introduced. In particular, the authors stated that famotidine was selected since it represented the most widely used agent for conventional therapy. You should decide whether they are valid comparators in your own setting.
Validity of estimate of measure of effectiveness
The effectiveness analysis considered two reviews of the literature, aimed at identifying relevant studies from which probability values for the decision model could be derived. It was not clear whether the reviews were conducted in a systematic manner, but specific inclusion criteria for the primary studies were reported. The authors selected the most reliable evidence and adopted weighting schemes when pooling the data derived from the primary studies. A conservative approach was used when selecting the probability values used in the model. The authors also made some assumptions and uncertainty was investigated in sensitivity analysis. Thus, the internal validity of the analysis was high. However, the authors did not consider compliance with triple therapy and the possibility of implementing re-eradication therapy.
Validity of estimate of measure of benefit
The benefit measure used in the economic analysis was DFDs, which represent a widely used end point in the treatments of patients with duodenal or gastric ulcer. It was obtained by modelling, and appropriate discounting was performed due to the long time horizon of the analysis. The decision models were described and there was a clear diagram of the model structure. The authors stressed that their model reflected actual clinical practice in Japan, although some effectiveness data came from foreign sources. The use of DFDs makes it difficult to compare the benefits of the present study with those from other interventions funded by the health service payer.
Validity of estimate of costs
The perspective adopted in the study was stated. It appears that all the relevant categories of costs have been included in the analysis. A detailed breakdown of the costs was reported and the unit costs were mentioned. However, the quantities of resources used were not reported, as they were based on the probability rates used in the decision model. The price year was stated, thus facilitating reflation exercises in other settings. The costs were treated deterministically and no sensitivity analyses were conducted on the cost inputs. The cost estimates were derived from national sources and appear to have been specific to the study setting. The authors made some assumptions to derive resource use, such that the decision model reflected Japanese practice patterns. Discounting was relevant and was performed. It would have been interesting had the authors evaluated the impact of indirect costs on the analysis, as they are clearly relevant to the patient domain studied.
